Pfizer-BioNTech COVID-19 Vaccine (BNT162b2)

• On 14 January 2021, the Food and Drug Administration (FDA) issued authorization (amended on 28 May 2021) granting Pfizer, Inc. the emergency use approval of Pfizer-BioNTech COVID-19 Vaccine.

  Product Information for Healthcare Professionals
  English     Tagalog

Product Information for Vaccine Recipients
English     Tagalog

• The Pfizer-BioNTech COVID-19 Vaccine is authorized on the basis of regulatory reliance to the United States Food and Drug Administration.
• Information regarding Pfizer-BioNTech COVID-19 Vaccine is being updated regularly and is available here.
• Information on the safety of Pfizer-BioNTech COVID-19 Vaccine is discussed in their comprehensive Risk Management Plan.
• For more information on reporting side effects, click here.